NextCure reports Q1 net loss $16.1M, cash $145.5M; pipeline data expected Q4 2023

NextCure, Inc.

2023-Q1 EPS reported -$0.58

Net loss $16.1M for Q1 2023 vs $20.6M loss in Q1 2022, narrowing on lower R&D expenses.
Cash $145.5M down from $159.9M; expects runway into mid-2025.
Three clinical programs (NC410, NC762, NC525) data updates expected in Q4 2023.
First patient dosed with NC525 (LAIR-1 mAb) Phase 1 in AML in Feb 2023.
R&D expenses decreased to $11.6M from $15.0M YoY.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

NextCure, Inc. reported financial results for the quarter ended March 31, 2023.

Period: the quarter ended March 31, 2023
Result: reported results

Exact text from the filing

NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases today provided a business update and reported first quarter 2023 financial results.

View on SEC.gov

Browse all earnings releases →

NextCure, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-008118

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.